JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Home・Akcijų sąrašas・LivaNova PLC

LivaNova PLC

Uždarymo kaina

50.29 2.76

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

48.68

Max

49.71

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-383M -327M
Pardavimai	-4.9M 317M
P/E Sektoriaus vid.	31.716 34.393
Pelnas, tenkantis vienai akcijai	0.88
Pelno marža	-103.303
Darbuotojai	2,900
EBITDA	-371M -286M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+48.71% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-10-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	326M 2.3B
Ankstesnė atidarymo kaina	47.53
Ankstesnė uždarymo kaina	50.29

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

36.34 / N/A Palaikymas ir pasipriešinimas

LivaNova PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-11 17:49; UTC

Pagrindinės rinkos jėgos

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025-08-11 17:18; UTC

Pagrindinės rinkos jėgos

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025-08-11 16:25; UTC

Uždarbis

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025-08-11 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-08-11 23:42; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-08-11 23:42; UTC

Rinkos pokalbiai

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025-08-11 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025-08-11 23:32; UTC

Rinkos pokalbiai

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025-08-11 23:02; UTC

Rinkos pokalbiai

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025-08-11 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-08-11 20:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025-08-11 20:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025-08-11 20:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement 2Q Rev $25.8M >EXOD

2025-08-11 20:14; UTC

Rinkos pokalbiai

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025-08-11 19:12; UTC

Rinkos pokalbiai

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025-08-11 18:56; UTC

Rinkos pokalbiai

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025-08-11 18:31; UTC

Rinkos pokalbiai

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025-08-11 17:43; UTC

Rinkos pokalbiai

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025-08-11 17:28; UTC

Rinkos pokalbiai

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025-08-11 17:16; UTC

Rinkos pokalbiai

Commodity Longs Fall to 11-Month Low -- Market Talk

2025-08-11 16:42; UTC

Įsigijimai, susijungimai, perėmimai

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025-08-11 16:27; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Says Sabadell Offer Remains in Effect

2025-08-11 16:26; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025-08-11 16:25; UTC

Įsigijimai, susijungimai, perėmimai

Banco de Sabadell Announced TSB Sale on July 1

2025-08-11 16:25; UTC

Įsigijimai, susijungimai, perėmimai

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Akcijų palyginimas

Kainos pokytis

LivaNova PLC Prognozė

Kainos tikslas

By TipRanks

48.71% į viršų

12 mėnesių prognozė

Vidutinis 73.7 USD 48.71%

Aukščiausias 168 USD

Žemiausias 50 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines LivaNova PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių LivaNova PLC akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

36.34 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę LivaNova PLC

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.